What monitoring is required when initiating and continuing fampridine therapy, including renal function assessment, gait testing, and surveillance for seizures, dizziness, falls, urinary retention, and cardiac arrhythmias?

Monitoring Requirements for Fampridine

Renal function must be assessed before starting fampridine and monitored at least annually during treatment, with creatinine clearance (CrCl) calculated using the Cockcroft-Gault equation 1. This is the most critical monitoring requirement, as fampridine is nearly completely (96%) eliminated unchanged in urine and carries significant seizure risk in patients with renal impairment 2.

Pre-Treatment Assessment

Before initiating fampridine, you must:

• Calculate estimated CrCl using Cockcroft-Gault formula (multiply by 0.85 for women) 1
• Exclude patients with CrCl ≤50 mL/min (absolute contraindication) 1
• Screen for seizure history (absolute contraindication) 1
• Establish baseline walking speed using Timed 25-Foot Walk (T25FW) or 12-item MS Walking Scale (MSWS-12) 3

Critical Renal Function Thresholds

• CrCl >80 mL/min: Standard dosing acceptable
• CrCl 51-80 mL/min (mild impairment): Plasma levels may reach 68-101% higher than normal, approaching levels seen with 15 mg twice daily dosing; carefully weigh benefits against seizure risk 1, 2
• CrCl ≤50 mL/min: Contraindicated 1

During Treatment Monitoring

Renal Function Surveillance

Monitor CrCl at least annually throughout treatment 1. This is particularly important in patients over age 50, as mild renal impairment is common in this population 1.

Response Assessment

Evaluate treatment response at minimum 2 weeks after initiation 3:

• Repeat T25FW or MSWS-12 testing
• Continue treatment only if patient demonstrates:
  • Decreased T25FW time, OR
  • Increased MSWS-12 scores
• Re-evaluate response at least every 6 months 3

Seizure Surveillance

Educate patients to immediately report any seizure activity 1, 4. Key facts about seizure risk:

• Incidence: 3.1 medically confirmed seizures per 1,000 patient-years in post-marketing data 4
• 12% of seizures occur within the first week of treatment 4
• Seizures can occur from first dose to >4 years of treatment 4
• If seizure occurs: discontinue immediately and do not restart 1

The majority of seizures occurred in patients without prior seizure history and at the recommended 10 mg twice daily dose 1, 4.

Adverse Event Monitoring

Monitor for common adverse effects at each visit 1, 2, 5:

• Dizziness (3.7% incidence)
• Insomnia (3.2%)
• Balance disorder/falls (3-5.4%)
• Urinary tract infection (2-11.5%)
• Headache (2.4%)
• Nausea (2.1%)

Rare but Serious Events

Anaphylaxis and severe hypersensitivity reactions: Though rare (13 cases in 107,000 patients over 5 years), these require immediate discontinuation 4. Instruct patients to report signs of allergic reactions.

Special Populations

Elderly Patients (≥65 years)

Renal function assessment is particularly critical in elderly patients, as they are more likely to have decreased renal function even with normal serum creatinine 1. Consider more frequent renal monitoring (e.g., every 6 months) in this population.

Patients with Cardiovascular Risk Factors

While fampridine showed low risk of QT prolongation in thorough QT studies 2, the LIBERATE real-world study included patients with pre-existing cardiovascular risk factors without identifying new safety concerns 6. Standard cardiovascular monitoring based on individual risk factors is appropriate, but no specific cardiac monitoring protocol is required for fampridine itself.

Key Monitoring Pitfalls to Avoid

1. Do not use MDRD or CKD-EPI eGFR for dosing decisions—only Cockcroft-Gault CrCl is validated for fampridine dosing 1
2. Do not continue treatment in non-responders—24.9% of patients discontinued due to lack of efficacy in real-world data 6
3. Do not restart after seizure—this is an absolute contraindication to further use 1
4. Do not overlook mild renal impairment (CrCl 51-80 mL/min)—these patients have significantly elevated drug levels and seizure risk 1, 2

No Routine Monitoring Required For

• Liver function tests
• Complete blood counts
• Electrocardiograms (unless clinically indicated)
• Ophthalmologic examinations
• Pulmonary function tests

These are not part of fampridine monitoring protocols, unlike some other neurologic medications 1, 3.